Results 81 to 90 of about 61,737 (200)

Hepatitis E Infection in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 3, March 2026.
ABSTRACT Opportunistic infections are increasingly recognised in patients with inflammatory bowel disease (IBD), particularly among those receiving immunosuppressive therapy. Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide, yet its relevance in IBD remains insufficiently clarified.
Dionysios Kogias, Georgios Kouklakis, Vasileios Papadopoulos   +2 more
wiley   +1 more source

Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice

Antiviral Research, 2017
Zika fever, a mosquito‐borne infectious disease caused by Zika virus (ZIKV), is an epidemic disease for which no effective therapy has been established.
Naganori Kamiyama, Ryusuke Soma, S. Hidano, Kei Watanabe, Hiroshi Umekita, Chiaki Fukuda, K. Noguchi, Y. Gendo, T. Ozaki, A. Sonoda, N. Sachi, L. Runtuwene, Y. Miura, E. Matsubara, S. Tajima, T. Takasaki, Y. Eshita, Takashi Kobayashi   +17 more
semanticscholar   +1 more source

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment

Drug Safety, 2017
IntroductionSignificant teratogenic effects have been demonstrated in all animal species exposed to ribavirin. Ribavirin is prescribed for chronic hepatitis C and is contraindicated in women who are pregnant and in the male sexual partners of women who ...
Susan M. Sinclair, Judith K Jones, Richard K. Miller, M. Greene, P. Kwo, W. Maddrey   +5 more
semanticscholar   +1 more source

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Gut, 2018
Objective We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed
G. Shiha, G. Esmat, M. Hassany, R. Soliman, M. Elbasiony, Rabab Fouad, A. Elsharkawy, Radi Hammad, W. Abdel-Razek, Talaat Zakareya, K. Kersey, B. Massetto, A. Osinusi, Sophia Lu, D. Brainard, J. Mchutchison, I. Waked, W. Doss   +17 more
semanticscholar   +1 more source

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

Gastroenterology, 2015
BACKGROUND & AIMS Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection.
Michael P. Curry, X. Forns, Raymond T. Chung, Norah A. Terrault, Robert S. Brown, J. Fenkel, F. Gordon, Jacqueline O’Leary, A. Kuo, T. Schiano, G. Everson, E. Schiff, A. Befeler, E. Gane, S. Saab, J. Mchutchison, G. Subramanian, W. Symonds, J. Denning, L. Mcnair, S. Arterburn, E. Svarovskaia, D. Moonka, N. Afdhal   +23 more
semanticscholar   +1 more source

Ribavirin for treating Crimean Congo haemorrhagic fever

Cochrane Database of Systematic Reviews, 2017
Background Crimean Congo haemorrhagic fever (CCHF) is a tick‐borne disease that occurs in parts of Asia, Europe and Africa. Since 2000 the infection has caused epidemics in Turkey, Iran, Russia, Uganda and Pakistan.
Samuel Johnson, N. Henschke, N. Maayan, I. Mills, B. Buckley, A. Kakourou, R. Marshall   +6 more
semanticscholar   +1 more source

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus

CPT: Pharmacometrics & Systems Pharmacology, 2016
Ribavirin remains an important component of hepatitis C treatment in certain clinical scenarios, but it causes hemolytic anemia. A quantitative understanding of the ribavirin exposure‐anemia relationship is important in dose individualization ...
LS Wu, LC Jimmerson, CE MacBrayne, JJ Kiser, DZ D'Argenio   +4 more
doaj   +1 more source

Gilbert’s syndrome and antiviral therapy of hepatitis C

Annals of Hepatology, 2009
Treatment of chronic hepatitis C with type I interferons and ribavirin can be associated with exacerbation of hepatitis and sometimes liver decompensation.
Katja Deterding, Kurt Grüngreiff, Tim O. Lankisch, Andrej Potthoff, Matthias J. Bahr, Michael P. Manns, Heiner Wedemeyer, Christian P. Strassburg   +7 more
doaj   +1 more source

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

BMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed, Hafiz Ghulam Murtaza Saleem, Sajjad Ullah, Shahzad Latif, Shabana, Junaid Jafar, Ahmad Bilal Waqar   +6 more
doaj   +1 more source

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

New England Journal of Medicine, 1998
J. Mchutchison, S. Gordon, E. Schiff, M. Shiffman, William M. Lee, V. Rustgi, Z. Goodman, M. Ling, S. Cort, J. Albrecht   +9 more
semanticscholar   +1 more source